Report : A-Z CDF items in Formulary 18/01/2021 16:00:29

[Back]

Section Status CDF Name 08.01.05 Formulary Abemaciclib Verzenios® 08.01.05 Restricted Use Aflibercept Zaltrap® 08.01.05 Restricted Use Atezolizumab Tecentriq® 08.01.01 Restricted Use Bendamustine  08.01.05 Restricted Use Bevacizumab Avastin® 08.01.05 Formulary Bortezomib  08.01.05 Restricted Use Brentuximab vedotin Adcetris® 08.01.05 Restricted Use Brigatinib Alunbrig® 08.01.05 Formulary Cetuximab Erbitux® 08.01.03 Restricted Use Clofarabine  08.01.05 Restricted Use Dabrafenib Tafinlar® 08.01.05 Restricted Use Daratumumab Darzalex® 08.01.05 Restricted Use Dasatinib Sprycel® 08.01 Restricted Use Durvalumab  08.01.05 Formulary Encorafenib Braftovi® 08.01.05 Formulary Entrectinib Rozlytrek ® 08.01.05 Restricted Use Everolimus Afinitor® 08.01.05 Restricted Use Ibrutinib Imbruvica® 08.01.05 Restricted Use Inotuzumab Ozogamicin  Besponsa® 08.01.05 Restricted Use Ipilimumab Yervoy® 08.01.05 Restricted Use Isatuximab Sarclisa® 08.01.05 Restricted Use Ixazomib Ninlaro® 08.01.05 Restricted Use Larotrectinib Vitrakvi® 08.02.04 Restricted Use Lenalidomide  08.01.05 Restricted Use Lenvatinib Lenvima® 08.01.02 Restricted Use Liposomal Cytarabine-Daunorubicin Vyxeos® 08.01.03 Restricted Use Nelarabine Atriance® 08.02.04 Restricted Use Niraparib Zejula® 08.01.05 Restricted Use Panitumumab Vectibix® 08.01.02 Restricted Use Pegylated-liposomal doxorubicin Caelyx® 08.01.05 Restricted Use Pembrolizumab Keytruda® 08.01.05 Restricted Use Ponatinib Iclusig® 08.03.04.01 Restricted Use Ribociclib Kisqali® 08.02.04 Restricted Use Rucaparib Rubraca® 08.01.05 Restricted Use Sunitinib Sutent® 08.01.05 Restricted Use Temsirolimus Torisel® 08.02.04 Formulary Tisagenlecleucel  Kymriah® 08.01.05 Restricted Use Trametinib Mekinist® 08.01.05 Restricted Use Venetoclax Venclyxto® 08.01.05 Restricted Use Vismodegib Erivedge®

Nottinghamshire Area Prescribing Committee